$ALZN
Alzamend Neuro, Inc. Stock $alzn

$alzn Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000121465924013191 Filed on July 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$755.8K	$666.6K	$3.483M
YoY Change	-34.84%	-59.77%	-53.09%
% of Gross Profit
Research & Development	$206.6K	$183.4K	$6.455M
YoY Change	-91.27%	-88.87%	-13.31%
% of Gross Profit
Depreciation & Amortization	$12.69K	$12.68K	$50.74K
YoY Change	0.0%	137.9%	119.94%
% of Gross Profit
Operating Expenses	$962.4K	$850.1K	$9.938M
YoY Change	-72.7%	-74.28%	-33.17%
Operating Profit	-$962.4K		-$9.938M
YoY Change	-72.7%		-33.17%
Interest Expense	$12.01K	-$1.470K	$10.10K
YoY Change	554.28%	182.69%	-231.18%
% of Operating Profit
Other Income/Expense, Net	-$12.01K		-$10.10K
YoY Change	554.28%		31.16%
Pretax Income	-$974.4K	-$851.5K	-$9.948M
YoY Change	-72.4%	-74.24%	-33.14%
Income Tax
% Of Pretax Income
Net Earnings	-$974.4K	-$851.5K	-$9.948M
YoY Change	-72.38%	-74.24%	-33.14%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.25		-$14.70
Diluted Earnings Per Share	-$1.25	-$1.24	-$14.70
COMMON SHARES
Basic Shares Outstanding	841.2K shares		676.6K shares
Diluted Shares Outstanding	777.8K shares		676.6K shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.194M	$376.1K	$376.1K
YoY Change	-29.77%	-92.69%	-92.69%
Cash & Equivalents	$1.194M	$376.0K
Short-Term Investments
Other Short-Term Assets	$222.2K	$79.19K	$79.19K
YoY Change	-69.13%	-88.6%	-88.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.416M	$455.2K	$455.2K
YoY Change	-41.32%	-92.2%	-92.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$253.7K	$176.3K	$176.4K
YoY Change	18.31%	120.87%	120.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$253.7K	$176.3K	$176.4K
YoY Change	18.31%	120.85%	120.85%
TOTAL ASSETS
Total Short-Term Assets	$1.416M	$455.2K	$455.2K
Total Long-Term Assets	$253.7K	$176.3K	$176.4K
Total Assets	$1.670M	$631.6K	$631.6K
YoY Change	-36.46%	-89.32%	-89.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.882M	$2.925M	$2.925M
YoY Change	5.15%	1.91%	1.91%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$300.7K	$300.7K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.882M	$3.226M	$3.226M
YoY Change	5.19%	12.39%	12.39%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.882M	$3.226M	$3.226M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.882M	$3.226M	$3.226M
YoY Change	5.15%	12.39%	12.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$54.99M	-$54.02M
YoY Change	15.53%	22.57%
Common Stock	$86.00	$69.00
YoY Change	-99.11%	-99.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.212M	-$2.594M	-$2.594M
YoY Change
Total Liabilities & Shareholders Equity	$1.670M	$631.6K	$631.6K
YoY Change	-36.46%	-89.32%	-89.32%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$974.4K	-$851.5K	-$9.948M
YoY Change	-72.38%	-74.24%	-33.14%
Depreciation, Depletion And Amortization	$12.69K	$12.68K	$50.74K
YoY Change	0.0%	137.9%	119.94%
Cash From Operating Activities	-$1.056M	-$1.427M	-$8.270M
YoY Change	-67.99%	-36.17%	-7.32%
INVESTING ACTIVITIES
Capital Expenditures	$90.00K	$0.00	$147.2K
YoY Change	-40.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$90.00K	$0.00	-$147.2K
YoY Change	-38.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.252M
YoY Change			626112.5%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.964M	1.520M	$3.652M
YoY Change		759845.0%	1826112.5%
NET CHANGE
Cash From Operating Activities	-$1.056M	-1.427M	-$8.270M
Cash From Investing Activities	-$90.00K	0.000	-$147.2K
Cash From Financing Activities	$1.964M	1.520M	$3.652M
Net Change In Cash	$817.9K	93.19K	-$4.765M
YoY Change	-123.74%	-104.17%	-46.6%
FREE CASH FLOW
Cash From Operating Activities	-$1.056M	-$1.427M	-$8.270M
Capital Expenditures	$90.00K	$0.00	$147.2K
Free Cash Flow	-$1.146M	-$1.427M	-$8.417M
YoY Change	-66.77%	-36.17%	-5.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001677077
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2024Q2	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital		usd
CY2023Q2	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital		usd
CY2024Q2	alzm	Note Receivable For Common Stock Related Party NoteReceivableForCommonStockRelatedParty		usd
CY2023	alzm	Issuance Of Common Stock For Restricted Stock Awards IssuanceOfCommonStockForRestrictedStockAwards		usd
CY2024	alzm	Issuance Of Common Stock For Restricted Stock Awards IssuanceOfCommonStockForRestrictedStockAwards		usd
CY2024	alzm	Subscription Receivable Payment Received SubscriptionReceivablePaymentReceived		usd
CY2024	alzm	Return Of Common Stock For Subscription Receivable ReturnOfCommonStockForSubscriptionReceivable		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2023	alzm	Proceeds From Issuance Of Preferred Stock Related Party ProceedsFromIssuanceOfPreferredStockRelatedParty		usd
CY2023	alzm	Return Of Common Stock For Cancellation Of Subscription Receivable ReturnOfCommonStockForCancellationOfSubscriptionReceivable		usd
CY2023	alzm	Debt Discount From Issuance Of Note Payable DebtDiscountFromIssuanceOfNotePayable		usd
CY2023	alzm	Fair Value Of Warrants Issued In Connection With Preferred Stock Related Party FairValueOfWarrantsIssuedInConnectionWithPreferredStockRelatedParty		usd
CY2024	alzm	Issuance Of Common Stocks For Related Party Payable IssuanceOfCommonStocksForRelatedPartyPayable		usd
CY2024Q2	alzm	Prepaid Clinical Trial Fees PrepaidClinicalTrialFees		usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals		usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2024	alzm	Shares Available For Grant Options Granted SharesAvailableForGrantOptionsGranted		shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024	alzm	Shares Available For Grant Options Exercised SharesAvailableForGrantOptionsExercised		shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-40483
CY2024	dei	Entity Registrant Name EntityRegistrantName	ALZAMEND NEURO, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1822909
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	3480 Peachtree Road NE
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Second Floor Suite 103
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	6700000	usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	841240	shares
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	dei	Auditor Firm AuditorFirmId	200
CY2024	dei	Auditor Name AuditorName	HASKELL & WHITE LLP
CY2024	dei	Auditor Location AuditorLocation	Irvine, California
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	376048	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5140859	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79194	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	447589	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	247334	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	455242	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	5835782	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	176346	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79843	usd
CY2024Q2	us-gaap	Assets Assets	631588	usd
CY2023Q2	us-gaap	Assets Assets	5915625	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2925059	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2870122	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	300714	usd
CY2024Q2	us-gaap	Liabilities Liabilities	3225773	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2870122	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	687999	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	687999	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	69	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	65	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	51426154	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62001395	usd
CY2023Q2	alzm	Note Receivable For Common Stock Related Party NoteReceivableForCommonStockRelatedParty	-14883295	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54020408	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-2594185	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	631588	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6455107	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3482538	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	9937645	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-9937645	usd
CY2024	us-gaap	Interest Expense InterestExpense	10101	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10101	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-9947746	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.70
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-14.70
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-22.89
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-22.89
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	676565	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	676565	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	650126	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	650126	shares
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13351511	usd
CY2023	alzm	Stockbased Compensation To Employees And Consultants StockbasedCompensationToEmployeesAndConsultants	3582625	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	200	usd
CY2023	alzm	Issuance Of Common Stock For Related Party Payable IssuanceOfCommonStockForRelatedPartyPayable	989334	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14878167	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3045503	usd
CY2024	alzm	Issuance Of Common Stock For Cash IssuanceOfCommonStockForCash	1252425	usd
CY2024	alzm	Issuance Of Preferred Stock For Cash IssuanceOfPreferredStockForCash	2100000	usd
CY2024	alzm	Stockbased Compensation To Employees And Consultants StockbasedCompensationToEmployeesAndConsultants	955633	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-9947746	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2594185	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-9947746	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-14878167	usd
CY2024	us-gaap	Depreciation Depreciation	50740	usd
CY2023	us-gaap	Depreciation Depreciation	23066	usd
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	714	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	955633	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3582625	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-368395	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	97866	usd
CY2024	alzm	Increase Decrease In Prepaid Expenses Related Party IncreaseDecreaseInPrepaidExpensesRelatedParty	-247334	usd
CY2023	alzm	Increase Decrease In Prepaid Expenses Related Party IncreaseDecreaseInPrepaidExpensesRelatedParty	-739918	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	54937	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1707272	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8269993	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8923152	usd
CY2024	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	147243	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-147243	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1252425	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200	usd
CY2024	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	300000	usd
CY2024	alzm	Proceeds From Issuance Of Preferred Stock Related Party ProceedsFromIssuanceOfPreferredStockRelatedParty	2100000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3652425	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	200	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4764811	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-8922952	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5140859	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14063811	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	376048	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5140859	usd
CY2024	alzm	Return Of Common Stock For Cancellation Of Subscription Receivable ReturnOfCommonStockForCancellationOfSubscriptionReceivable	-14883295	usd
CY2024	alzm	Debt Discount From Issuance Of Note Payable DebtDiscountFromIssuanceOfNotePayable	10000	usd
CY2024	alzm	Fair Value Of Warrants Issued In Connection With Preferred Stock Related Party FairValueOfWarrantsIssuedInConnectionWithPreferredStockRelatedParty	1902140	usd
CY2023	alzm	Issuance Of Common Stocks For Related Party Payable IssuanceOfCommonStocksForRelatedPartyPayable	989334	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Cash Cash	376000	usd
CY2024Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	54000000.0	usd
CY2024	us-gaap	Profit Loss ProfitLoss	9900000	usd
CY2024	alzm	Cash Used In Operating Activities CashUsedInOperatingActivities	8300000	usd
CY2023Q2	us-gaap	Cash Cash	5100000	usd
CY2023Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	44100000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zY9lw4Fui5g1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zwFNv3QO8cnf">Accounting Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s critical accounting policies that involve significant judgment and estimates include research and development, stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p>
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	360949	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	189053	shares
CY2019Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P12M
CY2023Q2	alzm	Prepaid Clinical Trial Fees PrepaidClinicalTrialFees	352635	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	60522	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	92154	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	18672	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2800	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	79194	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	447589	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-9947746	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-14878167	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9947746	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14878167	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	241500	usd
CY2024Q2	alzm	Deferred Tax Assets Tax Deferred Expense Capitalized Research Expenditures DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchExpenditures	2321972	usd
CY2023Q2	alzm	Deferred Tax Assets Tax Deferred Expense Capitalized Research Expenditures DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchExpenditures	1426779	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10838412	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6885428	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2638820	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2276109	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15799204	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10829816	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	32400	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	16767	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15766804	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10813049	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.289	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.183	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.498	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.048	pure
CY2024	alzm	Stock Compensation Rate StockCompensationRate	-0.001	pure
CY2023	alzm	Stock Compensation Rate StockCompensationRate	0.003	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.020	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15766804	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10813049	usd
CY2024Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	usd
CY2024	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	61278	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	98722	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	182.31
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M4D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	819900	usd
CY2024	alzm	Shares Available For Grant Options Expired SharesAvailableForGrantOptionsExpired	722	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	722	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	750.00
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	62000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	98000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	178.12
CY2024	alzm	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y2M19D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	70500	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	91334	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	178.31
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y11M23D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	70500	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	90208	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	177.51
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y11M8D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	70500	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	333	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	375.00
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	166	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	375.00
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	167	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	375.00
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	955633	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3582625	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	240449	shares
CY2024Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y10M24D
CY2024Q2	alzm	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	67.45
CY2024Q2	alzm	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	30449	shares
CY2024Q2	alzm	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	449.91
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001

Files In Submission

Name	View Source	Status
alzm-20240430_cal.xml	Edgar Link	unprocessable
0001214659-24-013191-index-headers.html	Edgar Link	pending
0001214659-24-013191-index.html	Edgar Link	pending
0001214659-24-013191.txt	Edgar Link	pending
0001214659-24-013191-xbrl.zip	Edgar Link	pending
alzlandscape.jpg	Edgar Link	pending
alzm-20240430.xsd	Edgar Link	pending
devpipline_v2.jpg	Edgar Link	pending
ex23_1.htm	Edgar Link	pending
ex23_2.htm	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex4_4.htm	Edgar Link	pending
ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
patientpopulation.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
alzm-20240430_def.xml	Edgar Link	unprocessable
alzm-20240430_lab.xml	Edgar Link	unprocessable
alzm-20240430_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
x71924010k.htm	Edgar Link	pending
x71924010k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALZN
Alzamend Neuro, Inc. Stock $alzn

2024 Q3 Form 10-K Financial Statement

#000121465924013191 Filed on July 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALZN Alzamend Neuro, Inc. Stock $alzn

2024 Q3 Form 10-K Financial Statement

#000121465924013191 Filed on July 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALZN
Alzamend Neuro, Inc. Stock $alzn